Lilly’s RET inhibitor LOXO-292 receives FDA priority review
Lilly recently announced that its RET inhibitor, selpercatinib (loxo-292), has been granted priority review status by the U.S. FDA and is expected to accelerate its approval for the treatment of […]
Read More →